Canaan files amendment showing 1.4% stake in Tyra

Canaan-affiliated investors amend Schedule 13G/A to report beneficial ownership in Tyra Biosciences.

Rhea-AI Filing Summary

Canaan-affiliated investors amend Schedule 13G/A to report beneficial ownership in Tyra Biosciences. The filing states Canaan XI L.P. and its general partner Canaan Partners XI LLC each have sole voting and dispositive power over 750,000 shares of Tyra common stock, representing 1.4% of the class. The percent is calculated using 53,867,115 shares outstanding as of February 25, 2026. The amendment also states that Canaan 2020+ Co-Investment L.P. - Series 7 and its GP no longer beneficially own any shares as of March 31, 2026.

Insights

Institutional Ownership Analyst

Amendment documents a modest, disclosed passive stake by Canaan-affiliates.

The filing lists 750,000 shares under sole voting and dispositive control for Canaan XI and its GP, equal to 1.4% of the outstanding common stock based on 53,867,115 shares as of February 25, 2026. This is a routine beneficial-ownership disclosure under Schedule 13G/A that clarifies current holdings and removes prior holdings by a co-investment series.

Key dependencies include the accuracy of the outstanding-share base cited from the Annual Report. Subsequent amendments or Form 13D filings would change the public record; timing and additional acquisitions are not stated in the excerpt.

Key Figures

Canaan XI holdings: 750,000 shares Percent of class: 1.4% Shares outstanding used: 53,867,115 shares +1 more

4 metrics

Canaan XI holdings 750,000 shares sole voting/dispositive power reported in amendment

Percent of class 1.4% based on 53,867,115 shares outstanding as of Feb 25, 2026

Shares outstanding used 53,867,115 shares outstanding as of Feb 25, 2026 (source: issuer 10-K)

Series 7 ownership 0.00 shares Canaan Series 7 no longer beneficially owns shares as of Mar 31, 2026

Key Terms

Schedule 13G/A, beneficially owned, sole dispositive power, shares outstanding

4 terms

Schedule 13G/A regulatory

"Amendment No. 3 and SCHEDULE 13G/A heading"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Amount beneficially owned: (i) Canaan XI directly owns 750,000 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power legal

"Sole Dispositive Power 750,000.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

shares outstanding market

"53,867,115 shares of Common Stock outstanding as of February 25, 2026"

Shares outstanding are the total number of a company’s stock units held by all shareholders, including institutional investors and company insiders — think of them as the total number of slices of the company’s ownership pie. Investors use this number to calculate how much of the company each share represents, and it directly affects per-share measures like earnings per share, ownership percentage and valuation; when the slice count changes, an investor’s claim and the company’s per-share metrics change too.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Canaan XI hold in Tyra Biosciences (TYRA)?

Canaan XI beneficially owns 750,000 shares, representing 1.4% of Tyra's common stock. The percentage is calculated using 53,867,115 shares outstanding as of February 25, 2026.

Which Canaan entities filed the Schedule 13G/A amendment for TYRA?

The filing names Canaan XI L.P., Canaan Partners XI LLC, Canaan 2020+ Co-Investment L.P. - Series 7, and Canaan Partners 2020+ Co-Investment, LLC as reporting persons in the amendment.

Did Canaan 2020+ Series 7 retain any Tyra shares?

No. The amendment states that Canaan Series 7 no longer beneficially owns any shares as of March 31, 2026.

How is the 1.4% ownership percentage calculated?

The percentage is based on 53,867,115 shares outstanding as of February 25, 2026, cited from Tyra's Annual Report on Form 10-K filed on March 2, 2026.

What voting and disposition powers are reported for Canaan XI?

Canaan XI and Canaan XI GP each report sole voting power and sole dispositive power over 750,000 shares of common stock, with no shared powers listed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 04:15 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Tyra Biosciences, Inc.

(Name of Issuer)

COMMON STOCK, $0.0001 PAR VALUE PER SHARE

(Title of Class of Securities)

90240B106

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Canaan XI L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 750,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 750,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

750,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.4 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Based on 53,867,115 shares of Common Stock outstanding as of February 25, 2026, as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2026.

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Canaan Partners XI LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 750,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 750,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

750,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.4 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Based on 53,867,115 shares of Common Stock outstanding as of February 25, 2026, as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2026.

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Canaan 2020+ Co-Investment L.P. - Series 7

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Canaan Partners 2020+ Co-Investment LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tyra Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 2656 State Street, Carlsbad, CA 92008
Item 2.
(a)	Name of person filing: (i) Canaan XI L.P., a Cayman Islands limited partnership ( "Canaan XI"); (ii) Canaan Partners XI LLC, a Delaware limited liability company ("Canaan XI GP"); (iii) Canaan 2020+ Co-Investment L.P. - Series 7, a Delaware limited partnership ("Canaan Series 7"); and (iv) Canaan Partners 2020+ Co-Investment, LLC, a Delaware limited liability company ("Canaan 2020+ GP").
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is 855 Oak Grove, Suite 201, Menlo Park, California 94025.
(c)	Citizenship: See Item 2(a) above.
(d)	Title of class of securities: COMMON STOCK, $0.0001 PAR VALUE PER SHARE
(e)	CUSIP No.: 90240B106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Canaan XI directly owns 750,000 shares of Common Stock, which represents approximately 1.4% of the outstanding shares of Common Stock. (ii) Canaan XI GP is the general partner of Canaan XI and may be deemed to beneficially own 750,000 shares of Common Stock, which represents approximately 1.4% of the outstanding shares of Common Stock. (iii) Canaan Series 7 no longer beneficially owns any shares of Common Stock as of March 31, 2026. (iv) Canaan 2020+ GP is the general partner of Canaan Series 7 and no longer beneficially owns any shares of Common Stock as of March 31, 2026.
(b)	Percent of class: The percent of class of the outstanding shares of Common Stock beneficially owned by the Reporting Persons in Item 4(a) are based on 53,867,115 shares of Common Stock outstanding as of February 25, 2026, as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Canaan XI: 750,000 shares of Common Stock; (2) Canaan XI GP: 750,000 shares of Common Stock; (3) Canaan Series 7: 0 shares of Common Stock; and (4) Canaan 2020+ GP: 0 shares of Common Stock.
	(ii) Shared power to vote or to direct the vote: None.
	(iii) Sole power to dispose or to direct the disposition of: (1) Canaan XI: 750,000 shares of Common Stock; (2) Canaan XI GP: 750,000 shares of Common Stock; (3) Canaan Series 7: 0 shares of Common Stock; and (4) Canaan 2020+ GP: 0 shares of Common Stock.
	(iv) Shared power to dispose or to direct the disposition of: None.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Canaan XI L.P.

Signature:	/s/ Nancy Levenson
Name/Title:	Nancy Levenson, Attorney-in-Fact
Date:	04/24/2026

Canaan Partners XI LLC

Signature:	/s/ Nancy Levenson
Name/Title:	Nancy Levenson, Attorney-in-Fact
Date:	04/24/2026

Canaan 2020+ Co-Investment L.P. - Series 7

Signature:	/s/ Nancy Levenson
Name/Title:	Nancy Levenson, Attorney-in-Fact
Date:	04/24/2026

Canaan Partners 2020+ Co-Investment LLC

Signature:	/s/ Nancy Levenson
Name/Title:	Nancy Levenson, Attorney-in-Fact
Date:	04/24/2026